You are here

Amino acid derived urea based chemicals as sEH inhibitor

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 1R41HL078016-01A1
Agency Tracking Number: HL078016
Amount: $100,000.00
Phase: Phase I
Program: STTR
Solicitation Topic Code: N/A
Solicitation Number: N/A
Timeline
Solicitation Year: N/A
Award Year: 2005
Award Start Date (Proposal Award Date): N/A
Award End Date (Contract End Date): N/A
Small Business Information
3912 Trust Way
Hayward, CA 94545
United States
DUNS: N/A
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 BRUCE HAMMOCK
 (530) 752-7519
 kdooley@ucdavis.edu
Business Contact
 JOHN HAMER
Phone: (510) 785-7060
Email: jhamer@aretetherapeutics.com
Research Institution
 UNIVERSITY OF CALIFORNIA
 
UNIVERSITY OF CALIFORNIA DAVIS SPONSORED PROGRAMS, 118 EVERSON HALL
DAVIS, CA 95616
United States

 Nonprofit College or University
Abstract

DESCRIPTION (provided by applicant): Recent findings indicate that increasing levels of epoxides of arachidonic acid (EETs) appear to be new and excellent means to treat both hypertension and vascular inflammation. We demonstrated that in vivo inhibition of soluble epoxide hydrolase resulted in higher levels of EETs and in reduction of blood pressure and inflammation in animal models. Because the effectiveness and length of action were less than optimal for first generation of sEH inhibitors and that the compounds could only be given i.p., the focus of this phase I application is to obtain potent sEH inhibitors with adequate physical properties for oral availability. Toward this objective, we will first produce a fluorescent assay to establish a high throughput screen. A combinatorial library will be made and screened using this enzymatic fluorescent assay. A secondary screen of measurement of physical properties will be used on the new human sEH inhibitors with picomolar Kl, to select a handful of compounds. Physical properties and oral availability will be then measured on this handfull of compounds. In the Phase II work, Arete Therapeutics will use the high throughput assay developed here to widen it search for potentially orally available new inhibitors of sEH. This will be done by screening the combinatorial libraries from the "NIH Roadmap," libraries contracted from commercial vendors, and more defined libraries generated in house. In addition, we will take the most potent compounds generated in the Phase I, which also have good physical properties, and synthesize them on a larger scale (0.5-1.0 g) for determining ADME in mice and rats. The compounds with the best pharmacokinetic properties will be used in rat models for hypertension, vascular inflammation and renal inflammation.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government